Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Chung Shan Medical University
  3. Pure學術人才庫轉入
  4. Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty
 
  • Details
Options

Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty

Other Title
A real-world analysis
Journal
PLOS ONE
Date Issued
2025-08-01
Author(s)
TING-HSING CHAO  
DOI
10.1371/journal.pone.0330434
URI
https://www.scopus.com/pages/publications/105013646738
https://scholars.csmu.edu.tw/handle/123456789/22765
Abstract
Background Cilostazol has been shown to improve walking distance in patients with lower extremity arterial disease (LEAD) and may reduce restenosis after revascularization. However, its long-term prognostic impact in real-world settings remains underexplored. Methods We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database (2012–2022). We included stable LEAD patients who had undergone percutaneous transluminal angioplasty (PTA) and remained event-free for 1 year. Stabilized inverse probability of treatment weighting (IPTW) was applied to adjust for baseline confounders. The study aimed to evaluate the effect of cilostazol on major adverse cardiovascular events (MACE), major adverse limb events (MALE), and composite bleeding outcomes. Results Among 5,300 stable LEAD patients, of whom 844 received cilostazol alone, 1,786 received aspirin or clopidogrel, and 2,670 received cilostazol combined with aspirin or clopidogrel. After IPTW, there were no significant differences between cilostazol monotherapy and any antiplatelet therapy groups regarding MACE, MALE, or composite bleeding outcomes (aHR [95% CI] = 0.84 [0.68–1.03], p = 0.09; 0.84 [0.70–1.01], p = 0.06; 0.88 [0.71–1.10], p = 0.26, respectively). In secondary outcomes, cilostazol treatment was associated with a reduced rate of subsequent angioplasty (aHR [95% CI] = 0.80 [0.60–0.98], p = 0.03). There were no significant differences in clinical outcomes when comparing cilostazol monotherapy to cilostazol combined with antiplatelet therapy. Conclusion In this real-world Asian cohort, cilostazol showed similar prognostic benefits and safety compared to standard antiplatelet therapy. These findings support its role in the long-term management of LEAD patients following PTA, particularly in Asian populations.
Type
journal article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback